ZXDB: A Drug Target and Biomarker for Various Diseases (G158586)
ZXDB: A Drug Target and Biomarker for Various Diseases
ZXDB (ZNF905) is a drug target and a biomarker for the treatment of various diseases, including cancer. It is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression and has been associated with the development and progression of various diseases.
ZXDB was first identified in 2012 using RNA sequencing techniques and has since been shown to play a role in the regulation of gene expression in various organisms, including humans. Studies have shown that ZXDB can interact with various transcription factors, including nuclear factor E2F1, to regulate gene expression.
One of the most promising aspects of ZXDB is its potential as a drug target. ZXDB has been shown to interact with various signaling pathways, including the PI3K/Akt signaling pathway, which is involved in the regulation of cell survival and growth. This suggests that ZXDB may be a useful target for the treatment of diseases that are characterized by the over-expression of genes that have been associated with this signaling pathway, such as cancer.
In addition to its potential as a drug target, ZXDB has also been shown to be a valuable biomarker for the diagnosis and prognosis of various diseases. Studies have shown that the expression of ZXDB is significantly altered in various diseases, including cancer, and that these changes can be used as biomarkers for disease diagnosis and prognosis.
The expression of ZXDB has also been shown to be regulated by various factors, including genetic and environmental factors. This suggests that ZXDB may be a useful biomarker for the diagnosis and prognosis of diseases that are characterized by the regulation of gene expression.
In conclusion, ZXDB is a drug target and biomarker for the treatment of various diseases, including cancer. Its potential as a drug target is based on its interaction with various signaling pathways, including the PI3K/Akt signaling pathway. ZXDB is also a valuable biomarker for the diagnosis and prognosis of various diseases due to its expression changes in response to genetic and environmental factors. Further research is needed to fully understand the potential of ZXDB as a drug and biomarker.
Protein Name: Zinc Finger X-linked Duplicated B
Functions: Cooperates with CIITA to promote transcription of MHC class I and MHC class II genes
The "ZXDB Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZXDB comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
